rVWF: treatment finally reaches the modern age.
Publication
, Journal Article
Metjian, AD
Published in: Blood
October 22, 2015
In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD).
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
October 22, 2015
Volume
126
Issue
17
Start / End Page
1975 / 1976
Location
United States
Related Subject Headings
- von Willebrand Factor
- von Willebrand Diseases
- Recombinant Proteins
- Male
- Immunology
- Humans
- Hemostatics
- Female
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Metjian, A. D. (2015). rVWF: treatment finally reaches the modern age. Blood, 126(17), 1975–1976. https://doi.org/10.1182/blood-2015-08-664052
Metjian, Ara D. “rVWF: treatment finally reaches the modern age.” Blood 126, no. 17 (October 22, 2015): 1975–76. https://doi.org/10.1182/blood-2015-08-664052.
Metjian AD. rVWF: treatment finally reaches the modern age. Blood. 2015 Oct 22;126(17):1975–6.
Metjian, Ara D. “rVWF: treatment finally reaches the modern age.” Blood, vol. 126, no. 17, Oct. 2015, pp. 1975–76. Pubmed, doi:10.1182/blood-2015-08-664052.
Metjian AD. rVWF: treatment finally reaches the modern age. Blood. 2015 Oct 22;126(17):1975–1976.
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
October 22, 2015
Volume
126
Issue
17
Start / End Page
1975 / 1976
Location
United States
Related Subject Headings
- von Willebrand Factor
- von Willebrand Diseases
- Recombinant Proteins
- Male
- Immunology
- Humans
- Hemostatics
- Female
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology